Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours By Ogkologos - February 17, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer March 21, 2023 Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... June 7, 2022 A Painful Breast Lump May Be Mistaken For Cancer When It’s... July 15, 2020 Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... March 23, 2021 Load more HOT NEWS Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... ESMO’s Expert Consensus: Do Not Discontinue or Delay Cancer Treatment That... Shannen Doherty Reveals She Has Stage IV Breast Cancer Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to...
